Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Anti-Angiogenic Properties of Ginsenoside Rg3

Title: Anti-Angiogenic Properties of Ginsenoside Rg3
Authors: M Nakhjavani; E Smith; AR Townsend; TJ Price; JE Hardingham
Publication Year: 2020
Subject Terms: Medicinal and biomolecular chemistry not elsewhere classified; Organic chemistry not elsewhere classified; Theoretical and computational chemistry not elsewhere classified; Science & Technology; Life Sciences & Biomedicine; Physical Sciences; Biochemistry & Molecular Biology; Chemistry; Multidisciplinary; ginsenoside Rg3; 20(S)-ginsenoside Rg3; 20(R)-ginsenoside Rg3; angiogenesis; epimer; ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; IONIZATION MASS-SPECTROMETRY; PANAX-GINSENG; HEPATOCELLULAR-CARCINOMA; INHIBITS ANGIOGENESIS; COLLAGEN-SYNTHESIS; PROSTATE-CANCER; 3404 Medicinal and biomolecular chemistry; 3206 Medical biotechnology; 3214 Pharmacology and pharmaceutical sciences
Description: Ginsenoside Rg3 (Rg3) is a member of the ginsenoside family of chemicals extracted from Panax ginseng. Like other ginsenosides, Rg3 has two epimers: 20(S)-ginsenoside Rg3 (SRg3) and 20(R)-ginsenoside Rg3 (RRg3). Rg3 is an intriguing molecule due to its anti-cancer properties. One facet of the anti-cancer properties of Rg3 is the anti-angiogenic action. This review describes the controversies on the effects and effective dose range of Rg3, summarizes the evidence on the efficacy of Rg3 on angiogenesis, and raises the possibility that Rg3 is a prodrug.
Document Type: article in journal/newspaper
Language: unknown
Relation: http://hdl.handle.net/10536/DRO/DU:30159018
Availability: http://hdl.handle.net/10536/DRO/DU:30159018; https://figshare.com/articles/journal_contribution/Anti-Angiogenic_Properties_of_Ginsenoside_Rg3/20634951
Rights: CC BY 4.0
Accession Number: edsbas.94C8C5B7
Database: BASE